Clinical Trials Browser

Has results × Plasmacytoma × daratumumab × Clear all

NCT02136134 2025-08-29

Addition of Daratumumab to Combination of Bortezomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma

Phase 3 Completed

498 enrolled 15 charts

Multiple Myeloma, Plasmacytoma